Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Lung Cancer

In brief

The purpose of this study is to determine the antitumor activity (response rate, time to tumor progression, survival) and safety of docetaxel in combination with talabostat in patients with advanced non-small cell lung cancer (NSCLC) who have failed a prior platinum-containing regimen.

Key facts

Study ID

NCT00080080

Run by

Point Therapeutics

Last updated by the study team

2007-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed Stage IIIb/IV NSCLC
• Failed or relapsed after receiving a platinum-containing chemotherapy regimen as first-line therapy for advanced NSCLC
• Measurable disease
• ECOG Performance Status of 0 or 1
• Expected survival ≥12 weeks
• Provide written informed consent

You may not qualify if…

• More than 2 prior chemotherapy regimens
• Brain metastases (exception: patients who have had a resection and/or completed a course of cranial irradiation, have no worsening CNS symptoms, and have discontinued all corticosteroids for that indication for at least 1 month)
• Any malignancy within the 5 years immediately prior to the first dose of study medication with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix
• The need for chronic (i.e., >7 days) oral or intravenous corticosteroid therapy
• A history of severe hypersensitivity reactions to drugs formulated with polysorbate 80
• A history of myocardial infarction within 1 year of study entry, CABG within 6 months of study entry, severe congestive heart failure (ejection fraction <30%), history of ventricular arrhythmia, or other uncontrolled cardiac arrhythmia
• Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol
• Patients who are within 30 days of chemotherapy, radiation therapy, immunotherapy, or other investigational medication for NSCLC. Patients must have recovered from all of the side effects of treatment in order to be enrolled.
• Pregnant or lactating women.
• Clinically significant laboratory abnormalities, specifically:
• Total bilirubin ≥institutional upper limit of normal (ULN); Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥1.5 x ULN concomitant with alkaline phosphatase >2.5 x ULN; Hepatitis B surface antigen or antibody to Hepatitis C (anti-HCV antibody); Serum creatinine ≥2.0mg/dL; or Granulocytes <1500/μL or platelets <100,000/μL.

Where it is running

• Cancer Center of Florida — Ocoee, Florida, United States
• University of Chicago — Chicago, Illinois, United States
• Van Elslander Cancer Center — Grosse Pointe Woods, Michigan, United States
• New York Oncology/Hematology--Albany Regional Cancer Center — Albany, New York, United States
• Mt. Sinai School of Medicine — New York, New York, United States
• USB Cancer Center-- Nyack Hospital — Nyack, New York, United States
• Dayton Oncology & Hematology — Kettering, Ohio, United States
• Mary Crowley Medical Research Center — Dallas, Texas, United States
• Tyler Cancer Center — Tyler, Texas, United States
• Cancer Care Northwest — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.